Scholars Central

Conference abstractPublished 17 Sep 2018

TriMix and antigen mRNA based vaccination

Authors: Karine Breckpot

Vrije Universiteit Brussel, Belgium

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Our immune system can detect and destroy cancer cells. However, growing cancer cells camouflage themselves as well as possible, blocking the attack of the immune system, or worse, they hijack certain cells of the immune system and turn them into cancer-promoting cells. In an attempt to stop this process, scientists want to boost the immune system. This can be done through cancer vaccination. The rationale is to provide the immune system with the identification card of cancer cells (tumor antigens) as well as an adjuvant to alarm the immune system. Several cancer vaccination strategies have been developed, among which the use of dendritic cells engineered in the laboratory using mRNA. We studied mRNA as a tool to deliver tumor antigens and immune modulating proteins, in particular, a mix of three mRNA molecules encoding the co-stimulatory molecule CD70 and two DC activation stimuli, CD40 ligand, and active TLR4 referred to as TriMix mRNA. Vaccination of stage III/IV melanoma patients with this dendritic cell vaccine have proven to be safe and well tolerated, to induce tumor antigen-specific immune responses and more importantly to induce objective clinical responses in over a quarter of patients. Although promising, ex vivo engineered cell-based vaccines are patient-specific and therefore time and money consuming. To generate a widely applicable cancer vaccine, it is important to immediately activate the dendritic cells in the patient's body. Therefore we studied several ways to deliver tumor antigen and/or TriMix mRNA to dendritic cells in situ. We studied several routes of delivery, including intranodal, intratumoral and intravenous. Linked to the systemic delivery of mRNA we studied several modes of mRNA encapsulation, including the use of lipids and polymers. The results of these studies will be presented and discussed in view of the current state-of-the-art.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Karine Breckpot”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels